Truth-Based Discovery Engine
Truth-Based Discovery Engine
The Speed of AI, The Truth of Biophysics
The Speed of AI, The Truth of Biophysics
Novorex integrates AI, FBDD (fragment-based drug discovery), and biophysical validation to generate proprietary experimental data and accelerate the discovery of novel small-molecule therapeutics.
Novorex integrates AI, FBDD (fragment-based drug discovery), and biophysical validation to generate proprietary experimental data and accelerate the discovery of novel small-molecule therapeutics.
Core Message
The competitive edge is no longer finding more hits, but validating the right ones faster and more accurately.
AI prediction can accelerate lead discovery, but predictions trained on public data remain hypotheses until experimentally validated. Novorex turns prediction into evidence through in-house SPR, NMR, X-ray crystallography, and wet-lab biophysical assays.
AI x FBDD x BiophysicsTruth-Based Discovery EngineValidated Proprietary Data
US$29.7M
Cumulative funding closed5+
Real binders and validated pipeline assets2020
Six years of validated in-house execution3 Labs
Pangyo, Central, and Jeongeup R&D infrastructureCore Value Proposition
From AI hypotheses to validated leads
AI alone is not enoughPublic-data predictions remain hypotheses and can increase late-stage risk without experimental confirmation.
Biophysical validation creates truth dataSPR, NMR, and X-ray validation confirm physical binding, target engagement, and structural insight.
Closed-loop DMTA compounds proprietary dataPrediction, synthesis, assay, SAR, and validation continuously improve decision quality.
Not just a platform companyNovorex is a drug developer with in-house CNS and inflammation pipelines and partnership-ready assets.